Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA3 | P07451 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | CA6 | P23280 | 1/20 | 0.40 |
| ▸ | CA5A | P35218 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29130540 | 0.94 | LMNA (0.35) | LMNACA12CA1CA2CA3 | |
| SCHEMBL8393138 | 0.84 | LMNA (0.41) | LMNACA12CA1CA2CA3 | |
| SCHEMBL9842718 | 0.82 | LMNA (0.48) | LMNACA12CA1CA2CA3 | |
| SCHEMBL5768011 | 0.80 | LMNA (0.44) | LMNACA12CA1CA2CA3 | |
| SCHEMBL4607223 | 0.76 | LMNA (0.41) | LMNACA12CA1CA2CA3 | |
| SCHEMBL28790145 | 0.73 | SLC6A2 (0.33) | LMNAALDH1A1MEN1KMT2A | |
| SCHEMBL8443526 | 0.73 | LMNA (0.48) | LMNACA12CA1CA2CA3 | |
| SCHEMBL169032 | 0.71 | LMNA (0.43) | LMNACA12CA1CA2CA3 | |
| SCHEMBL22228539 | 0.70 | LMNA (0.42) | LMNACA12CA1CA2CA3 | |
| SCHEMBL28225063 | 0.70 | LMNA (0.33) | LMNACA12CA1CA2CA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 157 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10947483-B2 | Encapsulates | PROCTER & GAMBLE INTERNATIONAL OPERATIONS SA (CH) | 2021-03-16 | — | — | US | claimed |
| US-10604728-B2 | Encapsulates | PROCTER & GAMBLE INTERNATIONAL OPERATIONS SA (CH) | 2020-03-31 | — | — | US | claimed |
| US-20200071639-A1 | Encapsulates | PROCTER & GAMBLE INT OPERATIONS SA (CH) | 2020-03-05 | — | — | US | claimed |
| CN-108165030-A | A kind of aqueous polymer pitch colloid and preparation method thereof | 江苏荣成路桥材料有限公司 | 2018-06-15 | — | — | CN | claimed |
| US-20170130172-A1 | ENCAPSULATES | PROCTER & GAMBLE (US) | 2017-05-11 | — | — | US | claimed |
| US-9475974-B2 | Controlling the stability of water in water emulsions | SCHLUMBERGER TECHNOLOGY CORPORATION (US) | 2016-10-25 | — | — | US | claimed |
| CN-103052386-B | Compositions containing tetracyclic compound | CHUGAI PHARMACEUTICAL CO.,LTD. (JP) | 2016-03-02 | — | — | CN | claimed |
| WO-2014189980-A1 | ENCAPSULATES | PGIOSA (CH) | 2014-11-27 | — | — | WO | claimed |
| EP-2806018-A1 | ENCAPSULATES | The Procter & Gamble Company (US) | 2014-11-26 | — | — | EP | claimed |
| US-20140342972-A1 | ENCAPSULATES | THE PROCTER & GAMBLE COMPANY (US) | 2014-11-20 | — | — | US | claimed |
| US-20100255102-A1 | STERILIZATION OF DISPERSIONS OF NANOPARTICULATE ACTIVE AGENTS WITH GAMMA RADIATION | ELAN PHARMA INTERNATIONAL LIMITED | 2010-10-07 | — | — | US | claimed |
| US-7507400-B2 | Water soluble depilatory having extended shelf life | SPINA THOMAS N | 2009-03-24 | — | — | US | claimed |
| WO-2006076097-A2 | STABLE NON-CRYSTALLINE FORMULATION COMPRISING LOSARTAN | NEKTAR THERAPEUTICS (US) | 2006-07-20 | — | — | WO | claimed |
| US-20060160871-A1 | Stable non-crystalline formulation comprising losartan | NEKTAR THERAPEUTICS (US) | 2006-07-20 | — | — | US | claimed |
| US-20050129964-A1 | Outer surface thereof being coated such that it reflects sunlight in near-infrared region, and inner surface thereof having low thermal emissivity; corrosion resistance | CONSTRUCTION RESEARCH & TECHNOLOGY GMBH (DE) | 2005-06-16 | — | — | US | claimed |
| EP-1137722-B1 | COATING WITH SPECTRAL SELECTIVITY | HUGO GERD (DE) | 2004-08-04 | — | — | EP | claimed |
| US-20030004522-A1 | Water soluble depilatory having extended shelf life | SPINA THOMAS N (US) | 2003-01-02 | — | — | US | claimed |
| US-20020188051-A1 | Coating with spectral selectivity | CONSTRUCTION RESEARCH & TECHNOLOGY GMBH (DE) | 2002-12-12 | — | — | US | claimed |
| EP-0487350-B1 | Coated receiver sheets | XEROX CORP (US) | 1996-03-13 | — | — | EP | claimed |
| EP-0064388-B1 | RETARD ORAL PHARMACEUTICAL COMPOSITIONS | CHINOIN Gyogyszer és Vegyészeti Termékek Gyára RT. (HU) | 1985-11-06 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200071639-A1 | Encapsulates | LIPA, TTPA, CHMP4B | LMNA 1015/4885CA12 1532/4885CA1 3244/4885 |
| US-10947483-B2 | Encapsulates | LIPA, TTPA, CHMP4B | LMNA 1015/4885CA12 1532/4885CA1 3244/4885 |
| US-20060160871-A1 | Stable non-crystalline formulation comprising losartan | REN, AGTR1, AGTR2 | LMNA 373/4885CA12 2813/4885CA1 2355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.